Drug products: NovoNorm®, Repaglinid Actavis, Repaglinid Arrow, Repaglinid Sandoz, Repaglinid STADA, Repaglinide Accord, Repaglinide Krka, Repaglinide Teva
ATC code: A10BX02
No clinically relevant sex differences have been described. A retrospective cohort study has shown a possible higher risk of hospitalized heart failure for women.
Some studies indicate that women have a higher risk of hypoglycemia during antidiabetic treatment than men.
No studies with a clinically relevant sex analysis regarding the pharmacokinetics of repaglinide have been found.
No studies with a clinically relevant sex analysis regarding the effect of repaglinide have been found.
In a retrospective cohort study from Taiwan including patients with type 2 diabetes treated with glinide (meglitinide/repaglinide) (14,357 men, 11,281 women) a higher risk of hospitalized heart failure was found for women (men: adjusted HR 1.26; 95%CI 0.95-1.68; women: adjusted HR 1.88; 95%CI 1.39-2.55) .The ACCORD study (Action to Control Cardiovascular Risk in Diabetes) was a randomized, controlled trial designed to test the effect of intensive glucose control compared with standard control on cardiovascular outcomes in patients with type 2 diabetes. The study showed that women had a higher risk of hypoglycemia than men regardless of treatment .Analyses of other insulins have shown a higher risk for women to have hypoglycemic events [7-11].
Oral contraceptives may reduce the hypoglycaemic effect of repaglinide . Regarding drug-drug interactions aspects, please consult Janusmed Interactions (in Swedish, Janusmed interaktioner).
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Two observational studies from the 1990’s (43 men, 374 women) reported intentional insulin omission among 1/3 of women to control their weight [2,3].
In a retrospective study in 124 women, peri-menstrual changes in self-reported glucose concentrations were found in 61%. Use of oral contraceptives did not diminish variability in blood glucose . In another study based on questionnaires (406 women) 67% of the participants reported changes in blood glucose levels or glycosuria pre-menstrually and 70% during the menstrual phase. Those with more cravings had larger elevations in blood glucose levels suggesting that giving in to cravings might cause the changes .
Date of litterature search: 2020-03-03
Reviewed by: Mia von Euler, Carl-Olav Stiller
Approved by: Karin Schenck-Gustafsson